Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
Key Points
Key Points
- Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
- NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.
Treatment
Treatme...
...For Patients with Stage II to IVA Nasophar...
...1.1For all nasopharyngeal carcinoma (NP...
...dation 1.2For all NPC patients, both s...
...ommendation 1.3For all NPC patients, a prescr...
...dation 1.4For all NPC patients, gross...
...commendation 1.5For NPC patients who have undergon...
...1.6The delineation of elective noda...
...erapy Sequence...
...tion 2.1For T2N0 (AJCC 8th) NPC patients,...
...ion 2.2For T1-2N1 (AJCC 8th) NPC p...
...2.3For Stage III–IVA (except T3...
...2.4For Stage III–IVA (except T3N0)...
...commendation 2.5For T3N0 (AJCC 8th) NPC patients,...
Concurrent Chemothera...
...endation 3.1For all NPC patients without con...
...3.2For all NPC patients without contraindi...
...endation 3.3For NPC patients with a contr...
...ation 3.4For NPC patients with a contraindi...
...tion Chemotherapy...
...commendation 4.1For all NPC patients receivi...
...tion 4.2For NPC patients receiving...
...n 4.3For NPC patients receiving induct...
...djuvant Chemotherapy
...dation 5.1For all NPC patients receiving adjuvant...
...mmendation 5.2For all NPC patients receiving...
...5.3For all NPC patients receiving adj...
Figure 1. Stage II to IVA Nasopharyngea...